AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 376.83B, AbbVie(ABBV) trades at $213.15. The stock has a price-to-earnings ratio of 90.27 and currently yields dividends of 3.1%.
During the trading session on 2026-03-31, AbbVie(ABBV) shares reached a daily high of $214.00 and a low of $210.40. At a current price of $213.15, the stock is +1.3% higher than the low and still -0.4% under the high.
Trading volume for AbbVie(ABBV) stock has reached 7.49M, versus its average volume of 8.61M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
In a report released on March 27, Evan Seigerman from BMO Capital maintained a Buy rating on AbbVie, with a price target of $258.00. Unlock hedge fund-level da...
Key Points The Schwab U.S. Dividend Equity ETF recently completed its annual reconstitution. It added two new healthcare stocks to its top 10. Healthcare is...
Advertisement AbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American...
Analyst ratings
67%
of 33 ratingsMore ABBV News
AbbVie (NYSE:ABBV) is presenting new clinical research across its dermatology portfolio at the 2026 American Academy of Dermatology Annual Meeting. The company...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie is running a global observational study called “Treat-to-Target and Disease Modificat...
A shareholder group has filed a proposal for AbbVie to require an independent Chair of the Board. AbbVie’s board is urging investors to vote against the propos...
Key Points The Federal Reserve is concerned about tariffs and higher oil prices driving inflation higher. The Fed faces a dilemma because economic growth has...
AbbVie (ABBV) announced a multi-year partnership with Major League Baseball, naming AbbVie the Official Pharmaceutical Partner of MLB beginning with the 2026 se...
Key Points Both companies have distributions boasting above-average yields. One is even a Dividend King. 10 stocks we like better than AbbVie › Even the mos...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.